Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

This study has been terminated.
(Difficulty with recruiting willing participants.)
Sponsor:
Information provided by (Responsible Party):
Deborah Minor, University of Mississippi Medical Center
ClinicalTrials.gov Identifier:
NCT00849810
First received: February 2, 2009
Last updated: March 18, 2013
Last verified: March 2013

February 2, 2009
March 18, 2013
January 2009
November 2010   (final data collection date for primary outcome measure)
Primary Outcome is Pre- and Post-treatment Ambulatory Blood Pressure. [ Time Frame: 4 weeks (pre- and post-treatment) ] [ Designated as safety issue: Yes ]
Primary outcome is pre- and post-treatment ambulatory blood pressure, basal metabolic rate, and quality of life. [ Time Frame: pre- and post-treatment ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00849810 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate
Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study

The purpose of the study is to compare the effects of nebivolol and metoprolol on 24-hour ambulatory blood pressure characteristics and basal metabolic rates in patients with hypertension.

Not Provided
Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypertension
  • Drug: Metoprolol
    Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
    Other Names:
    • Nebivolol is bystolic
    • Metoprolol is lopressor
  • Drug: Nebivolol
    5 - 20 mg daily, at a stable dose for 4 to 5 weeks
Experimental: Metoprolol to nebivolol
metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
Interventions:
  • Drug: Metoprolol
  • Drug: Nebivolol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1
November 2010
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years old or older
  • currently be treated at a University of MS Medical Center Internal Medicine Clinics
  • currently taking metoprolol succinate for hypertension
  • have their hypertension controlled (<140/90).

Exclusion Criteria:

  • uncontrolled hypertension
  • severe renal or moderate hepatic impairment
  • currently taking CYP 2D6 inducers/inhibitors
  • recent stroke (less than 6 months)
  • recent myocardial infarction (less than 6 months)
  • congestive heart failure
  • diagnosed obstructive sleep apnea
  • atrial fibrillation
  • arm circumference >50 cm
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00849810
2009-0002
Yes
Deborah Minor, University of Mississippi Medical Center
University of Mississippi Medical Center
Not Provided
Principal Investigator: Deborah Minor, PharmD University of Mississippi Medical Center
University of Mississippi Medical Center
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP